Novartis: Ovarian cancer drug disappoints in trial

May 27, 2010

(AP) -- Swiss drug maker Novartis AG said Thursday it won't ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

The drug, patupilone, failed to show improvements over existing drugs in 829 patients with advanced .

"Novartis does not plan to proceed with regulatory filings based on these data," the Basel-based company said.

Patupilone also is being tested for treatment of certain types of colorectal, lung and .

Shares in Novartis closed 1.6 percent higher at 51.85 Swiss francs ($45.01) in line with a general lift on the Zurich exchange.

Explore further: High-dose opioid prescribing continues to climb

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Novartis says on track to deliver US vaccine order

Oct 29, 2009

(AP) -- Swiss drugmaker Novartis AG said Thursday it is on track to meet its U.S. government order for swine flu vaccine, seeking to calm fears in recent weeks that shipments and vaccination programs may be delayed.

Roche to take over Genentech for $47 billion

Mar 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Caliban
1 / 5 (1) May 27, 2010
What a drag for Novartis!!! Not only do they lose billions in profits, but they have that much less capital to live up to the double-digit quarterly dividend that their shareholders demand.
This kind of failure is inevitable for as long as BigPharma relies on the "Profit Foremost" model of drug development. Currently, if a drug candidate shows any promise(as in, can we rush this to market?), then it will be fast-tracked in preference to another that may show greater effectiveness, but may take longer to develop, refine, and trial.
If it's all about cashflow and marketing, then the quality of the product is going to suffer, and so I laugh every time I see them step on their own dick like this. Just imagine if you or I indulged in this sort of planning. It would be just as wise to use a casino visit to determine your budget.